search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Implementation of population screening for colorectal cancer by repeated fecal occult blood test in the Netherlands


- candidate number3324
- NTR NumberNTR1327
- ISRCTNISRCTN wordt niet meer aangevraagd
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR26-mei-2008
- Secondary IDs120710007 
- Public TitleImplementation of population screening for colorectal cancer by repeated fecal occult blood test in the Netherlands
- Scientific TitleImplementation of population screening for colorectal cancer by repeated fecal occult blood test in the Netherlands
- ACRONYMCRC-SCR
- hypothesis
- Healt Condition(s) or Problem(s) studiedColorectal cancer, Faecal occult blood test, Screening
- Inclusion criteria1. Age 50-74
2. Living in Almere, Amsterdam
3. Watergraafsmeer, Diemen
- Exclusion criteria1. FOBT positive in first round
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingNone
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-jun-2008
- planned closingdate1-jun-2009
- Target number of participants10000
- InterventionsFOBT with collection paper vs FOBT without collection paper
- Primary outcome- Attendance rate
- Secondary outcome- Burden of FOBT
- Timepoints- Baseline (after completion of the test, before notification of the testresult)
- Trial web sitewww.proefbevolkingsonderzoekdarmkanker.nl
- statusplanned
- CONTACT FOR PUBLIC QUERIESResearch fellow M.J. Denters
- CONTACT for SCIENTIFIC QUERIESMD, PhD Evelien Dekker
- Sponsor/Initiator Academic Medical Center (AMC), Department of Gastroenterology
- Funding
(Source(s) of Monetary or Material Support)
ZON-MW, The Netherlands Organization for Health Research and Development
- PublicationsN/A
- Brief summaryColorectal cancer (CRC) is one of the major causes of death in the Netherlands, accounting for over 4500 deaths in 2005. CRC morbidity and mortality can be reduced by population screening. Of the currently available screening tests, the effectiveness of screening with fecal occult blood test (FOBT) is the only one with documented efficacy in randomized controlled clinical trials.
FOBT is a test with a relatively low sensitivity. On the other hand, it is not invasive and very cheap.
Biannual performance of FOBT could result in a cumulative yield that is competitive with the yield of screening with more sensitive tests performed less frequently. Most international guidelines on FOBT-based screening now recommend biannual screening.
The benefits of a screening program depend not only on the efficacy, but also on the participation rate.
Biannual screening is only feasible if the participation rate in such a screening program does not substantially decline during subsequent screening rounds.
So far, it is unclear to what extent screening participants respond positively to invitations for repeated screening in the Dutch situation and how many of them actually will participate in further screening rounds. Preliminary analysis of questionnaires from the first screening round of the Dutch FOBT implementation trial suggests that a significant percentage of the participants would not participate again in an FOBT-based screening program.
In this proposal we intend to study the implementation of repeated FOBT in participants of invitation-based FOBT population screening in the Netherlands. The study will build on the first implementation study of FOBT screening in the Amsterdam region which has almost been completed.
Eligible for the current study proposal will be the same 10.000 persons aged 50 to 74 years that were selected for the first screening round in the above mentioned implementation study. This group will consist of non participants of the first round as well as those that tested negative on the FOBT test.
Those people that were FOBT-positive but declined undergoing a colonoscopy will also be included in the second round. Only FOBT-positives that underwent a colonoscopy will be excluded since they have undergone the current gold standard of colon imaging. The above mentioned group ( 9.750 persons) will receive another invitation to participate in FOBT screening two years after the first invitation. In this study we intend to use the immunochemical FOBT (OC-Sensor). In case of a positive FOBT they will be referred for colonoscopy. The main outcome measure of this study is the second round participation rate.
Validated questionnaires, provided before and after test results, will measure patients' experience with the screening program. Most important aspects are the perception of the repeated FOBT, the understanding of the test results, the possibility to make a well-informed choice, and the preference of screening method. Furthermore, we will incorporate the results of this two-yearly FOBT-based population screening program in a model-based cost-effectiveness analysis of CRC-screening in the Netherlands.
The organization of the study will be done by the Departments of Gastroenterology and Hepatology and Clinical Epidemiology, Biostatistics and Bioinformatics in the AMC, together with the regional Comprehensive Cancer Center (IKA). The cost-effectiveness analysis will be performed in collaboration with the department of Public Health of the Erasmus MC.
The results of this implementation study will enable an evidence-based comparison of the different FOBT-strategies for CRC-screening in the Netherlands from a point of feasibility and cost-effectiveness.
- Main changes (audit trail)
- RECORD26-mei-2008 - 4-jun-2008


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl